CA3244907A1 - ARTIFICIAL EXPRESSION CONSTRUCTIONS TO MODULATE GENE EXPRESSION IN DOPAMINERGIC NEURONS - Google Patents
ARTIFICIAL EXPRESSION CONSTRUCTIONS TO MODULATE GENE EXPRESSION IN DOPAMINERGIC NEURONSInfo
- Publication number
- CA3244907A1 CA3244907A1 CA3244907A CA3244907A CA3244907A1 CA 3244907 A1 CA3244907 A1 CA 3244907A1 CA 3244907 A CA3244907 A CA 3244907A CA 3244907 A CA3244907 A CA 3244907A CA 3244907 A1 CA3244907 A1 CA 3244907A1
- Authority
- CA
- Canada
- Prior art keywords
- ehgt
- seq
- artificial
- enhancer
- coding sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313653P | 2022-02-24 | 2022-02-24 | |
| US63/313,653 | 2022-02-24 | ||
| PCT/US2023/063259 WO2023164643A2 (en) | 2022-02-24 | 2023-02-24 | Artificial expression constructs for modulating gene expression in dopaminergic neurons |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244907A1 true CA3244907A1 (en) | 2023-08-31 |
Family
ID=87766932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244907A Pending CA3244907A1 (en) | 2022-02-24 | 2023-02-24 | ARTIFICIAL EXPRESSION CONSTRUCTIONS TO MODULATE GENE EXPRESSION IN DOPAMINERGIC NEURONS |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250163458A1 (https=) |
| EP (1) | EP4482969A4 (https=) |
| JP (1) | JP2025508821A (https=) |
| AU (1) | AU2023226080A1 (https=) |
| CA (1) | CA3244907A1 (https=) |
| WO (1) | WO2023164643A2 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020097121A1 (en) * | 2018-11-05 | 2020-05-14 | Allen Institute | Artificial expression constructs for selectively modulating gene expression in excitatory cortical neurons |
-
2023
- 2023-02-24 CA CA3244907A patent/CA3244907A1/en active Pending
- 2023-02-24 US US18/841,086 patent/US20250163458A1/en active Pending
- 2023-02-24 JP JP2024550135A patent/JP2025508821A/ja active Pending
- 2023-02-24 EP EP23760978.9A patent/EP4482969A4/en active Pending
- 2023-02-24 AU AU2023226080A patent/AU2023226080A1/en active Pending
- 2023-02-24 WO PCT/US2023/063259 patent/WO2023164643A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4482969A4 (en) | 2026-05-06 |
| US20250163458A1 (en) | 2025-05-22 |
| JP2025508821A (ja) | 2025-04-10 |
| EP4482969A2 (en) | 2025-01-01 |
| WO2023164643A3 (en) | 2023-10-19 |
| WO2023164643A2 (en) | 2023-08-31 |
| AU2023226080A1 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230159952A1 (en) | Artificial expression constructs for selectively modulating gene expression in neocortical layer 5 glutamatergic neurons | |
| US20230117172A1 (en) | Artificial expression constructs for selectively modulating gene expression in non-neuronal brain cells | |
| US20250235550A1 (en) | Artificial expression constructs for modulating gene expression in the cerebellum and a secondary cell type | |
| WO2024163914A2 (en) | Artificial expression constructs for modulating gene expression in cells within the spinal cord | |
| US20240182923A1 (en) | Artificial expression constructs for modulating gene expression in claustrum neurons | |
| WO2023245013A2 (en) | Artificial expression constructs for modulating gene expression in non-neuronal central nervous system cells | |
| US20240254514A1 (en) | Artificial expression constructs for modulating gene expression in neurons within the thalamus | |
| US20240018543A1 (en) | Artificial expression constructs for modulating gene expression in chandelier cells | |
| US20230212608A1 (en) | Artificial expression constructs for selectively modulating gene expression in inhibitory neocortical neurons | |
| US20250163458A1 (en) | Artificial expression constructs for modulating gene expression in dopaminergic neurons | |
| US20250041454A1 (en) | Artificial expression constructs for modulating gene expression in neocortical layer 4 or layer 5 intratelencephalic neurons | |
| WO2025137554A1 (en) | Artificial expression constructs for modulating gene expression in serotonergic neurons | |
| WO2025179180A1 (en) | Artificial expression constructs for modulating gene expression in motor neurons and cerebellar neurons | |
| WO2025059552A1 (en) | Artificial expression constructs for modulating gene expression in the basal ganglia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240822 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240823 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240823 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240823 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250219 |